Veracyte, Inc. operates as a genomic diagnostics company in the United States. The company uses genomic technology to resolve diagnostic uncertainty. It offers Afirma Thyroid FNA Analysis solution; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients. The company's products also include Percepta Bronchial Genomic Classifier solution for use in lung cancer screening and diagnosis; and Envisia Genomic Classifier solution for idiopathic pulmonary fibrosis. Veracyte, Inc. sells its products through product specialists, institutional managers, account managers, and medical science specialists. Veracyte, Inc. has research collaboration agreement with Loxo Oncology to develop medicines for patients with genetically defined cancers. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VCYT
CUSIPN/A
Phone650-243-6300
Debt
Debt-to-Equity Ratio0.98
Current Ratio4.01
Quick Ratio3.71
Price-To-Earnings
Trailing P/E Ratio-11.10
Forward P/E Ratio-11.14
P/E GrowthN/A
Sales & Book Value
Annual Sales$71.95 million
Price / Sales4.81
Cash FlowN/A
Price / CashN/A
Book Value$1.09 per share
Price / Book9.20
Profitability
EPS (Most Recent Fiscal Year)($0.91)
Net Income$-31,000,000.00
Net Margins-38.69%
Return on Equity-91.03%
Return on Assets-41.36%
Miscellaneous
Employees246
Outstanding Shares34,530,000
Market Cap$355.69 million
Veracyte (NASDAQ:VCYT) Frequently Asked Questions
What is Veracyte's stock symbol?
Veracyte trades on the NASDAQ under the ticker symbol "VCYT."
How were Veracyte's earnings last quarter?
Veracyte Inc (NASDAQ:VCYT) posted its quarterly earnings data on Monday, July, 23rd. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.27) by $0.09. The biotechnology company earned $22.75 million during the quarter, compared to the consensus estimate of $20.67 million. Veracyte had a negative return on equity of 91.03% and a negative net margin of 38.69%. View Veracyte's Earnings History.
When is Veracyte's next earnings date?
What price target have analysts set for VCYT?
4 Wall Street analysts have issued twelve-month price targets for Veracyte's stock. Their predictions range from $9.00 to $13.00. On average, they expect Veracyte's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 9.7% from the stock's current price. View Analyst Price Targets for Veracyte.
What is the consensus analysts' recommendation for Veracyte?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Veracyte.
Are investors shorting Veracyte?
Veracyte saw a increase in short interest during the month of August. As of August 15th, there was short interest totalling 785,190 shares, an increase of 44.2% from the July 31st total of 544,533 shares. Based on an average daily volume of 376,158 shares, the days-to-cover ratio is currently 2.1 days. Approximately 3.2% of the company's shares are sold short. View Veracyte's Current Options Chain.
Who are some of Veracyte's key competitors?
Some companies that are related to Veracyte include InVitae (NVTA), CareDx (CDNA), RadNet (RDNT), Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), PotNetwork (POTN), Psychemedics (PMD), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), Cancer Genetics (CGIX), OpGen (OPGN), CBA Florida (CBAI), Biocept (BIOC) and Aeon Global Health (AGHC).
Who are Veracyte's key executives?
Veracyte's management team includes the folowing people:
- Ms. Bonnie H. Anderson, Co-Founder, Chairman & CEO (Age 60)
- Mr. Christopher M. Hall, Pres & COO (Age 49)
- Mr. Keith S. Kennedy CFA, CPA, CFO & Sec. (Age 48)
- Dr. Giulia C. Kennedy Ph.D., Chief Scientific Officer & Head of Scientific, Clinical and Medical Affairs Department (Age 59)
- Mr. Ashish Kheterpal, Chief Information Officer
Has Veracyte been receiving favorable news coverage?
Headlines about VCYT stock have been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Veracyte earned a media and rumor sentiment score of 0.18 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 46.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term. View Recent Headlines for Veracyte.
Who are Veracyte's major shareholders?
Veracyte's stock is owned by a variety of of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (10.89%), Acuta Capital Partners LLC (7.70%), Cannell Capital LLC (6.99%), BlackRock Inc. (6.05%), First Light Asset Management LLC (2.55%) and Millennium Management LLC (2.50%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones and Jesse I Treu. View Institutional Ownership Trends for Veracyte.
Which major investors are selling Veracyte stock?
VCYT stock was sold by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, Grandeur Peak Global Advisors LLC, Schwab Charles Investment Management Inc., Spark Investment Management LLC, Birchview Capital LP, Algert Global LLC and Renaissance Technologies LLC. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Christopher M Hall and Jesse I Treu. View Insider Buying and Selling for Veracyte.
Which major investors are buying Veracyte stock?
VCYT stock was bought by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Cannell Capital LLC, BlackRock Inc., Millennium Management LLC, Perkins Capital Management Inc., Quantum Capital Management, Royce & Associates LP and Essex Investment Management Co. LLC. View Insider Buying and Selling for Veracyte.
How do I buy shares of Veracyte?
Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Veracyte's stock price today?
One share of VCYT stock can currently be purchased for approximately $10.03.
How big of a company is Veracyte?
Veracyte has a market capitalization of $355.69 million and generates $71.95 million in revenue each year. The biotechnology company earns $-31,000,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Veracyte employs 246 workers across the globe.
How can I contact Veracyte?
Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]
MarketBeat Community Rating for Veracyte (NASDAQ VCYT)
MarketBeat's community ratings are surveys of what our community members think about Veracyte and other stocks. Vote "Outperform" if you believe VCYT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCYT will underperform the S&P 500 over the long term. You may vote once every thirty days.
